OTC · Healthcare

Pharma-Bio Serv, Inc. (PBSV)

As-reported financials and recent SEC filings for Pharma-Bio Serv, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$9.0M

Net income

$-100,463

Net margin

-1.1%

Diluted EPS

$-0.00

ROE

-0.8%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$9.0M	$9.5M	$17.0M	$19.4M	$20.1M
Gross profit	$2.9M	$2.5M	$5.1M	$4.9M	$5.4M
Operating income	$-637,662	$-1.3M	$1.1M	$1.2M	$-3.9M
Net income	$-100,463	$-777,619	$1.3M	$1.0M	$-2.1M
Diluted EPS	$-0.00	$-0.03	$0.06	—	—

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-06-15

10-Q2026-06-15

8-K2026-05-15

ARS2026-04-16

DEF 14A2026-04-16

8-K2026-03-17

10-Q2026-03-17

10-K/A2026-02-27

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on PBSV

Search Pharma-Bio Serv, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.